Chemotherapy Immunotherapy in Extensive Stage Small Cell with Thoracic Radiation therapy

CHEST RT is investigating the safety and effectiveness of combining chemotherapy and immunotherapy with chest radiation therapy for the treatment of extensive stage small cell lung cancer (ES-SCLC). For over 20 years, a combination of chemotherapy using etoposide with either cisplatin or carboplatin had been used to treat ES-SCLC. Adding immunotherapy to the chemotherapy combination has been shown to help boosts the body’s natural defences to fight cancer, improving response to treatment. This combination of chemotherapy with immunotherapy is now the standard of care treatment. Research has shown that radiation therapy also improves the ability of the immune system to recognise tumours. The researchers would like to investigate whether combining radiation therapy with the standard chemo/immunotherapy may further improve patients response to treatment.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

35

Final Accrual

35

Closing Date of Accrual

05 August 2024

Trial Chairperson

Dr Eric Hau, Westmead Hospital NSW

Dr Sagun Parakh, Austin Hospital, VIC

Trial Contact

chestrt@trog.com.au

Clinical Trial Registration

Related Post

17 November, 2026

Every kilometre counts: TROG supporters go the distance for cancer research

LATEST NEWS: 17 November 2026 From early morning walks

10 November, 2026

Golfers tee off for annual TROG fundraiser

LATEST NEWS: 10 November 2026 The Myall Coast Veteran